My Account Log in

4 options

Evolution of translational omics : lessons learned and the path forward / Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy ; Christine M. Micheel, Sharyl J. Nass, and Gilbert S. Omenn, editors ; Institutes of Medicine of the National Academies.

EBSCOhost Academic eBook Collection (North America) Available online

View online

Ebook Central Academic Complete Available online

View online

NCBI Bookshelf Available online

View online

National Academies Press Available online

View online
Format:
Book
Contributor:
Micheel, Christine.
Nass, Sharyl J.
Omenn, Gilbert S.
Institute of Medicine (U.S.). Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials.
Institute of Medicine (U.S.). Board on Health Sciences Policy.
National Academies Press (U.S.)
Language:
English
Subjects (All):
Genomics--Technology.
Genomics.
Genomics--Data processing.
Genetic translation--Technology.
Genetic translation.
Biomolecules--Analysis.
Biomolecules.
Biomolecules--Data processing.
Bioinformatics--Technology.
Bioinformatics.
Biotechnology.
Data mining--Analysis.
Data mining.
Physical Description:
1 online resource (338 p.)
Edition:
1st ed.
Place of Publication:
Washington, D.C. : National Academies Press, c2012.
Language Note:
English
Summary:
Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.
Contents:
""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figures, and Tables""; ""Summary""; ""1 Introduction""; ""2 Omics-Based Clinical Discovery: Science, Technology, and Applications""; ""3 Best Practices for Omics-Based Test Validation Prior to Use for Patient Management Decisions in a Clinical Trial Setting""; ""4 Evaluation of Omics-Based Tests for Clinical Utility and Use""; ""5 Responsible Parties""; ""6 Lessons from the Case Studies""; ""Appendix A: Case Studies""
""Appendix B: Gene Expression Based Tests Developed at Duke University and Used in Clinical Trials""""Appendix C: Introduction to Biomarkers""; ""Appendix D: Reporting Guidelines""; ""Appendix E: Committee Member and Staff Biographies""; ""Appendix F: Information Gathering Sessionsand Speakers""; ""Acronyms and Abbreviations""; ""Glossary""
Notes:
Description based upon print version of record.
Includes bibliographical references.
ISBN:
1-283-63640-9
0-309-22419-5
OCLC:
923288397

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account